Results 11 to 20 of about 3,746,463 (320)

Risk of Herpes Zoster in Individuals on Biologics, DMARDS and/or Corticosteroids for Autoimmune Diseases:A Systematic Review and Meta-Analysis [PDF]

Open Forum Infectious Diseases, 2016
Background: Studies examining the risk of herpes zoster (HZ) associated with immunosuppressants, such as biologics, non-biological disease modifying agents (nbDMARDs) or corticosteroids, have generated conflicting results.
Alarcón-Segovia, Bachelez, Bejarano, Bongartz, Braun, Brenner, Bresnihan, Cardiel, Che, Chen, Choy, Cohen, Cutolo, Dechartres, Dixon, Dixon, Dreiher, Egger, Emery, Emery, Fleischmann, Fleischmann, Furie, Furst, Galloway, Genovese, Genovese, Gupta, Gupta, Harpaz, Hayward, Higgins, Higgins, Hoes, Kameda, Kawai, Keystone, Kost, Kourbeti, Kremer, Kremer, Kremer, Kremer, Lal, Leonardi, Long, McDonald, Merrill, Moher, Moreland, Moutsopoulos, Nakajima, Nishimoto, Osterman, Oxman, Oxman, Papp, Pappas, Peto, Rutgeerts, Sampathkumar, Sandborn, Sandborn, Schiff, Schreiber, Segan, Shah, Singh, Smitten, Smolen, Smolen, Spittal, Strangfeld, Stroup, Sweeting, Takeuchi, Tanaka, Tanaka, van der Heijde, van Vollenhoven, Veetil, Weiner, Wells, Winthrop, Winthrop, Winthrop, Wolfe, Yamamoto, Yawn, Yawn, Youssef, Yun, Zhang, Zisman, Zorzela   +94 more
core   +4 more sources

The in vitro effect of antirheumatic drugs on platelet function

Platelets, 2020
Several antirheumatic drugs lower the cardiovascular risk among rheumatoid arthritis patients. It is, however, unknown whether inhibition of platelet function contributes to this risk reduction.
Camilla Brødsgaard Nielsen, Christian Nielsen, Mads Nybo, Søren Andreas Just, Pernille Just Vinholt   +4 more
doaj   +2 more sources

Combination of Second-line Antirheumatic Drugs [PDF]

Annals of Medicine, 1997
Single drug therapy is often not satisfactory in the treatment of chronic arthritis. The combination of second-line antirheumatic drugs is therefore increasingly employed. Various strategies of combining drugs can be used, starting with combinations or adding agents in case of insufficient effect of single therapy.
C.J. Haagsma, Piet L. C. M. van Riel
openalex   +6 more sources

Antirheumatic Drugs and the Risk of Tuberculosis [PDF]

Clinical Infectious Diseases, 2006
We aimed to quantify the rate of Mycobacterium tuberculosis disease (TB) among a cohort of patients with rheumatoid arthritis (RA) and to assess whether the independent use of disease-modifying antirheumatic drugs (DMARDs) is associated with the risk of developing TB.The study was performed using the PharMetrics Patient-Centric database (PharMetrics ...
Paul Brassard, Abbas Kezouh, Samy Suissa
openalex   +4 more sources

Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis

Therapeutic Advances in Musculoskeletal Disease, 2021
Objective: To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease ...
Chenghua Weng, Leixi Xue, Qing Wang, Wentian Lu, Jiajun Xu, Zhichun Liu   +5 more
doaj   +2 more sources

Aphthous colitis induced by non-steroidal antirheumatic drugs

Swiss Medical Weekly, 2003
I Zuber-Jerger
doaj   +2 more sources

Disease-modifying antirheumatic drugs [PDF]

Nursing, 2010
Jennifer M. Belavic
openalex   +4 more sources

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Annals of the Rheumatic Diseases, 2022
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.
J. Smolen, R. Landewé, S. Bergstra, A. Kerschbaumer, A. Sepriano, D. Aletaha, R. Caporali, C. Edwards, K. Hyrich, J. Pope, Savia de Souza, T. Stamm, T. Takeuchi, P. Verschueren, K. Winthrop, A. Balsa, J. Bathon, M. Buch, G. Burmester, F. Buttgereit, M. Cardiel, K. Chatzidionysiou, C. Codreanu, M. Cutolo, A. D. den Broeder, K. El Aoufy, A. Finckh, J. Fonseca, J. Gottenberg, E. Haavardsholm, A. Iagnocco, K. Lauper, Zhanguo Li, I. McInnes, E. Mysler, P. Nash, G. Poór, G. Ristić, F. Rivellese, A. Rubbert-Roth, H. Schulze-Koops, N. Stoilov, Anja Strangfeld, A. H. M. van der Helm-van Mil, E. van Duuren, T. V. Vliet Vlieland, R. Westhovens, D. M. van der Heijde   +47 more
semanticscholar   +1 more source

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

JAMA Network Open, 2023
This cohort study evaluates the incidence of interstitial lung disease in patients with rheumatoid arthritis who have been treated with biologic and targeted synthetic disease-modifying antirheumatic drugs.
Matthew C. Baker, Yuhan Liu, Rong Lu, Janice Lin, Jason H. Melehani, William H. Robinson   +5 more
semanticscholar   +1 more source

Repurposing haloperidol for the treatment of rheumatoid arthritis: an integrative approach using data mining techniques

Therapeutic Advances in Musculoskeletal Disease, 2021
Introduction: Treatment of rheumatoid arthritis (RA) has advanced with the introduction of biological disease-modifying antirheumatic drugs. However, more than 20% of patients with RA still have moderate or severe disease activity.
Chihiro Nakagawa, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada   +3 more
doaj   +1 more source